As of Jul 31, 2026, the Ligand Pharmaceuticals Inc - Class B stock's PE ratio is 36.4. This results from the current EPS of $7.9 and stock price of $287.54.
The PE ratio of Ligand Pharmaceuticals Inc - Class B has averaged 92.87 over the last ten years. The current PE ratio of 36.4 is 61% below the historical average. Over the past ten years, LGND's PE ratio was at its highest in the Sep 2020 quarter at 794.33, when the stock price was $95.32 and the EPS was $0.12. The lowest value was in the Dec 2019 quarter, when it reached 3.15 with a price of $104.29 and an EPS of $33.13.
Maximum annual decrease: -91.22% in 2018
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 29.36 | N/A | $189.07 | $6.44 |
| 2024 | N/A | N/A | $107.15 | -$0.22 |
| 2023 | 23.65 | N/A | $71.42 | $3.02 |
| 2022 | N/A | N/A | $66.8 | -$1.98 |
| 2021 | 44.9 | N/A | $154.46 | $3.44 |
| 2020 | N/A | N/A | $99.45 | -$0.18 |
| 2019 | 3.15 | -84.28% | $104.29 | $33.13 |
| 2018 | 20.04 | -91.22% | $135.7 | $6.77 |
| 2017 | 228.22 | N/A | $136.93 | $0.6 |
| 2016 | N/A | N/A | $101.61 | -$0.08 |
| 2015 | 9.34 | -89.64% | $108.42 | $11.61 |
| 2014 | 90.19 | -3.98% | $53.21 | $0.59 |
| 2013 | 93.93 | N/A | $52.6 | $0.56 |
| 2012 | N/A | N/A | $20.74 | -$0.03 |
| 2011 | 24.22 | N/A | $11.87 | $0.49 |
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | 25.27 | -13.93% | $199.65 | $7.9 |
| Dec 2025 | 29.36 | -61.71% | $189.07 | $6.44 |
| Sep 2025 | 76.68 | N/A | $177.14 | $2.31 |
| Jun 2025 | N/A | N/A | $113.68 | -$4.07 |
| Mar 2025 | N/A | N/A | $105.14 | -$7.2 |
| Dec 2024 | N/A | N/A | $107.15 | -$0.22 |
| Sep 2024 | 37.91 | 9.79% | $100.09 | $2.64 |
| Jun 2024 | 34.53 | 157.49% | $84.26 | $2.44 |
| Mar 2024 | 13.41 | -43.3% | $73.1 | $5.45 |
| Dec 2023 | 23.65 | -62.11% | $71.42 | $3.02 |
| Sep 2023 | 62.42 | 35.93% | $59.92 | $0.96 |
| Jun 2023 | 45.92 | -13.23% | $72.1 | $1.57 |
| Mar 2023 | 52.92 | N/A | $73.56 | $1.39 |
| Dec 2022 | N/A | N/A | $66.8 | -$1.98 |
| Sep 2022 | N/A | N/A | $86.11 | -$1.27 |
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
The current PE ratio of LGND is below the 3, 5 and 10-year averages.
With a P/E of 36.4, LGND is above the Healthcare sector, the industry and its peers average. Compared to its Healthcare sector average of 26.04, Ligand Pharmaceuticals Inc - Class B's P/E is 40% higher.
LGND's PE ratio is lower than its peer stocks LLY and MRK, but it is greater than JNJ's and AMGN's. Ligand Pharmaceuticals Inc - Class B is presently trading at a higher PE ratio (36.4) than its peer group average of 27.77.
| Stock name | PE ratio | Market cap |
|---|---|---|
| BMY Bristol-Myers Squibb Company | 14.24 | $132.33B |
| PFE Pfizer Inc | 19 | $141.86B |
| AMGN AMGEN Inc | 26.07 | $203.72B |
| JNJ Johnson & Johnson | 28.97 | $609.45B |
| MRK Merck & Co Inc | 35.6 | $313.87B |
| LGND Ligand Pharmaceuticals Inc - Class B | 36.34 | $5.75B |
| LLY Lilly(Eli) & Company | 39.63 | $1.05T |
| BAX Baxter International Inc | N/A | $14.46B |
The price to earnings ratio for LGND stock is 36.4 as of Jul 31, 2026.
The 3-year average PE ratio for LGND stock is 37.9.
The 5-year average PE ratio for LGND stock is 43.08.
The highest quarterly PE ratio in the last ten years has been 794.33 and it was in the Sep 2020 quarter.
LGND's price to earnings ratio is currently 61% below its 10-year historical average.
The PE ratio is calculated by dividing the most recent price of a stock by its trailing twelve months EPS. As of today (Jul 31, 2026), Ligand Pharmaceuticals Inc - Class B's stock price is $287.54. The earnings per share for the trailing twelve months (TTM) ending Mar 2026 is $7.9. Therefore, Ligand Pharmaceuticals Inc - Class B's P/E ratio for today is 36.4. PE RATIO(36.4) = STOCK PRICE($287.54) / TTM EPS($7.9)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.